Methoxsalen S.A.L.F. (Methoxsalen)

Methoxsalen intercalates into DNA and, upon activation by UVA light, creates cross‑links that block DNA synthesis. This suppresses excessive skin cell growth and modulates local immune responses, providing therapeutic effects in the targeted skin disorders.

The dosage of methoxsalen is individualized by the prescribing clinician based on the patient’s condition, skin type, and treatment protocol. Specific dosing regimens are determined during the medical assessment and should not be self‑prescribed.

Methoxsalen is generally contraindicated in pregnancy because of potential teratogenic effects, and its safety during breastfeeding has not been established. Women who are pregnant, planning pregnancy, or nursing should discuss alternative therapies with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methoxsalen is one of the most commonly used psoralens for UVA‑based phototherapy. Compared with alternatives such as 8‑methoxypsoralen, it has a well‑characterized safety profile and extensive clinical experience, though individual response and tolerability may vary.

Methoxsalen S.A.L.F. should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain stability.

Methoxsalen is administered extracorporeally, typically as a topical or oral preparation taken prior to controlled UVA exposure in a clinical setting. The exact route and timing are determined by the treating physician as part of a phototherapy protocol.

Serious risks include severe phototoxic burns, blistering, hematologic abnormalities such as leukopenia, hepatic dysfunction, and long‑term ocular toxicity like cataract formation. Patients should be monitored closely for any signs of these adverse events.

Methoxsalen should be avoided in individuals with a history of photosensitivity disorders, active liver disease, pregnant or potentially pregnant women, and patients taking contraindicated medications such as systemic retinoids or other strong photosensitizers.